Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D06EQP
|
||||
Former ID |
DAP001075
|
||||
Drug Name |
Aceprometazine
|
||||
Synonyms |
Aceprometazina; Aceprometazinum; Acepromethazine; Aceprometazina [INN-Spanish]; Aceprometazine [INN:DCF]; Aceprometazinum [INN-Latin]; Mepronizine (TN); KETONE, 10-(2-(DIMETHYLAMINO)PROPYL)PHENOTHIAZIN-2-YL METHYL; Ethanone, 1-(10-(2-(dimethylamino)propyl)-10H-phenothiazin-2-yl)-(9CI); 1-(10-(2-(Dimethylamino)propyl)-10H-phenothiazin-2-yl)ethanone; 1-[10-[2-(dimethylamino)propyl]phenothiazin-2-yl]ethanone; 1-{10-[2-(dimethylamino)propyl]-10H-phenothiazin-2-yl}ethanone; 10-(2-(Dimethylamino)propyl)phenothiazin-2-yl methyl ketone; 1664 CB
|
||||
Drug Type |
Small molecular drug
|
||||
Indication | Sleep disorders [ICD9: 307.4, 327, 780.5; ICD10:F51, G47] | Approved | [1] | ||
Therapeutic Class |
Antihistamines
|
||||
Structure |
![]() |
Download2D MOL |
|||
Formula |
C19H22N2OS
|
||||
Canonical SMILES |
CC(CN1C2=CC=CC=C2SC3=C1C=C(C=C3)C(=O)C)N(C)C
|
||||
InChI |
1S/C19H22N2OS/c1-13(20(3)4)12-21-16-7-5-6-8-18(16)23-19-10-9-15(14(2)22)11-17(19)21/h5-11,13H,12H2,1-4H3
|
||||
InChIKey |
XLOQNFNTQIRSOX-UHFFFAOYSA-N
|
||||
CAS Number |
CAS 13461-01-3
|
||||
PubChem Compound ID | |||||
PubChem Substance ID | |||||
Target and Pathway | |||||
Target(s) | Histamine H1 receptor | Target Info | Antagonist | [2] | |
KEGG Pathway | Calcium signaling pathway | ||||
Neuroactive ligand-receptor interaction | |||||
Inflammatory mediator regulation of TRP channels | |||||
PANTHER Pathway | Histamine H1 receptor mediated signaling pathway | ||||
Reactome | Histamine receptors | ||||
G alpha (q) signalling events | |||||
WikiPathways | Monoamine GPCRs | ||||
GPCRs, Class A Rhodopsin-like | |||||
IL-4 Signaling Pathway | |||||
Gastrin-CREB signalling pathway via PKC and MAPK | |||||
GPCR ligand binding | |||||
GPCR downstream signaling | |||||
References | |||||
REF 1 | Drug information of Aceprometazine, 2008. eduDrugs. | ||||
REF 2 | Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.